We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ESLT:TASEElbit Systems Ltd Analysis

Data as of 2026-03-11 - not real-time

$877.12

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Elbit Systems trades at $877.12, comfortably above its 20‑day ($774.72), 50‑day ($716.37) and 200‑day ($532.88) simple moving averages, while the 14‑day RSI sits at 68.6 and the MACD line remains bullish with a positive histogram, indicating strong short‑term momentum and an increasing volume trend. However, the stock’s valuation metrics are extreme: a trailing P/E of 89.3 versus an industry average of 29.4, a price‑to‑book of 10.1, and a DCF‑derived fair value of only $231.9, implying a downside of roughly 35% from current levels.
Recent contract wins totaling approximately $435 million (including a $228 million follow‑on Iron Fist APS deal) provide a clear catalyst for revenue growth, yet the company’s modest profit margin (5.9%), low dividend yield (0.34%) and modest payout ratio (22%) offer limited upside. Combined with high 30‑day volatility (≈47%) but a very low beta (0.23), the stock presents a classic case of strong technicals and news‑driven optimism against a fundamentally overvalued backdrop.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish technical indicators (price above SMAs, MACD bullish)
  • Recent high‑value contract awards boosting near‑term revenue
  • Extreme valuation metrics limiting upside potential

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Sustained contract pipeline over the next 3‑6 years
  • Persistently high P/E and price‑to‑book ratios
  • Moderate volatility with low systematic risk (beta)

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • DCF fair value far below current market price
  • Low dividend yield and modest payout ratio
  • High valuation multiples relative to peers and industry

Key Metrics & Analysis

Financial Health

Revenue Growth11.90%
Profit Margin5.91%
P/E Ratio89.3
ROE12.90%
ROA3.47%
Debt/Equity26.61
P/B Ratio10.1
Op. Cash Flow$913.1M
Free Cash Flow$484.0M
Industry P/E29.4

Technical Analysis

TrendBullish
RSI68.6
Support$651.86
Resistance$960.00
MA 20$774.72
MA 50$716.37
MA 200$532.88
MACDBullish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Fair Value$231.91
Target Price$566.50
Upside/Downside-35.41%
GradeOvervalued
TypeGrowth
Dividend Yield0.34%

Risk Assessment

Beta0.23
Volatility46.91%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.